Abstract
AbstractElectroencephalographic (EEG) signals are acquired non-invasively from electrodes placed on the scalp. Experts in the field can use EEG signals to distinguish between patients with Alzheimer’s disease (AD) and normal control (NC) subjects using classification models. However, the training of deep learning or machine learning models requires a large number of trials. Datasets related to Alzheimer’s disease are typically small in size due to the lack of AD patient samples. The lack of data samples required for the training process limits the use of deep learning techniques for further development in clinical settings. We propose to increase the number of trials in the training set by means of a decomposition–recombination system consisting of three steps. Firstly, the original signals from the training set are decomposed into multiple intrinsic mode functions via multivariate empirical mode decomposition. Next, these intrinsic mode functions are randomly recombined across trials. Finally, the recombined intrinsic mode functions are added together as artificial trials, which are used for training the models. We evaluated the decomposition–recombination system on a small dataset using each subject’s functional connectivity matrices as inputs. Three different neural networks, including ResNet, BrainNet CNN, and EEGNet, were used. Overall, the system helped improve ResNet training in both the mild AD dataset, with an increase of 5.24%, and in the mild cognitive impairment dataset, with an increase of 4.50%. The evaluation of the proposed data augmentation system shows that the performance of neural networks can be improved by enhancing the training set with data augmentation. This work shows the need for data augmentation on the training of neural networks in the case of small-size AD datasets.
Publisher
Springer Science and Business Media LLC
Subject
Cognitive Neuroscience,Computer Science Applications,Computer Vision and Pattern Recognition
Reference44 articles.
1. International AD. World Alzheimer report 2019: attitudes to dementia. Alzheimer’s Disease International London, UK; 2019.
2. Du X, Wang X, Geng M. Alzheimer’s disease hypothesis and related therapies. Translational neurodegeneration. 2018;7(1):1–7.
3. The Alzheimer Association. Alzheimer’s disease facts and figures. Alzheimer’s & Dementia. 2023Apr;19(4):1598–695. Available from: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13016.
4. Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimer’s & Dementia. 2022 Dec;18(12):2669-86. Available from: https://onlinelibrary.wiley.com/doi/10.1002/alz.12756.
5. Musha T, Asada T, Yamashita F, Kinoshita T, Chen Z, Matsuda H, et al. A new EEG method for estimating cortical neuronal impairment that is sensitive to early stage Alzheimer’s disease. Clinical Neurophysiology. 2002Jul;113(7):1052-8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1388245702001281.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献